GLP-1 Industry Blue Book

This blue book provides a comprehensive overview of the GLP-1 (glucagon-like peptide-1) industry, focusing on its market landscape, clinical applications, and future development trends. It explores the evolution of GLP-1 receptor agonists, highlighting their role in treating type 2 diabetes and obesity. The report examines the competitive landscape, key pharmaceutical companies, and the latest breakthroughs in long-acting formulations and multi-target therapies. Additionally, it discusses emerging trends, such as the expansion of GLP-1 applications into cardiovascular and kidney diseases, the rise of oral formulations, and challenges related to manufacturing capacity. The study also covers business development strategies, including licensing deals and partnerships, to accelerate commercialization. This document is an essential resource for pharmaceutical companies, investors, and healthcare professionals looking to understand the rapid growth of the GLP-1 industry.